Market Closed -
Nasdaq
01:30:00 08/05/2024 am IST
|
5-day change
|
1st Jan Change
|
3.04
USD
|
+3.05%
|
|
+4.83%
|
+25.62%
|
Fiscal Period: Juni |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
159.2
|
121.4
|
60.24
|
76.5
|
-
|
-
|
Enterprise Value (EV)
1 |
159.2
|
121.4
|
60.24
|
76.5
|
76.5
|
76.5
|
P/E ratio
|
-2.41
x
|
-17.9
x
|
-5
x
|
-6.65
x
|
-5.36
x
|
-4.34
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-2,23,14,660
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
23,345
|
23,345
|
25,633
|
25,933
|
-
|
-
|
Reference price
2 |
6.820
|
5.200
|
2.350
|
2.950
|
2.950
|
2.950
|
Announcement Date
|
22/09/21
|
09/09/22
|
20/09/23
|
-
|
-
|
-
|
Fiscal Period: June |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-3.614
|
-6.831
|
-11.78
|
-11.93
|
-18.01
|
-24.52
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-30.25
|
-6.826
|
-11.73
|
-11.77
|
-17.88
|
-24.36
|
Net income
1 |
-38.46
|
-6.826
|
-11.73
|
-11.77
|
-17.88
|
-24.36
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-2.830
|
-0.2900
|
-0.4700
|
-0.4433
|
-0.5500
|
-0.6800
|
Free Cash Flow
|
-
|
-5.44
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
22/09/21
|
09/09/22
|
20/09/23
|
-
|
-
|
-
|
Fiscal Period: June |
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-1.555
|
-1.071
|
-1.88
|
-2.325
|
-2.612
|
-3.813
|
-2.864
|
-2.494
|
-2.544
|
-2.76
|
-3.038
|
-3.589
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-1.553
|
-1.073
|
-1.876
|
-2.323
|
-2.612
|
-3.827
|
-2.798
|
-2.496
|
-2.481
|
-2.717
|
-3.007
|
-3.563
|
Net income
1 |
-1.553
|
-1.073
|
-1.876
|
-2.323
|
-2.612
|
-3.827
|
-2.798
|
-2.496
|
-2.481
|
-2.717
|
-3.007
|
-3.563
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.0700
|
-0.0500
|
-0.0800
|
-0.1000
|
-0.1100
|
-0.1500
|
-0.1100
|
-0.1000
|
-0.1000
|
-0.1100
|
-0.1167
|
-0.1233
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/11/21
|
11/02/22
|
11/05/22
|
09/09/22
|
10/11/22
|
10/02/23
|
11/05/23
|
20/09/23
|
14/11/23
|
13/02/24
|
-
|
-
|
Fiscal Period: June |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-5.44
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-0.3600
|
-0.2300
|
-0.3900
|
-0.3800
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
22/09/21
|
09/09/22
|
20/09/23
|
-
|
-
|
-
|
Last Close Price
2.95
USD Average target price
6
USD Spread / Average Target +103.39% Consensus |
1st Jan change
|
Capi.
|
---|
| +25.62% | 76.5M | | +21.74% | 46.81B | | -0.97% | 41.37B | | +47.07% | 41.29B | | -3.52% | 28.87B | | +11.12% | 26.06B | | -19.37% | 19.13B | | +31.18% | 12.39B | | -0.04% | 12.08B | | +0.39% | 11.96B |
Other Biotechnology & Medical Research
|